Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph early_phase_1

20%

Ph phase_1

20%

Ph phase_4

20%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Early Phase 1First-in-human

1(20.0%)

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

2(40.0%)

Phase 4Post-market surveillance

1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(2)

Other(1)

Detailed Status

Withdrawn2

Completed2

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (20.0%)

Phase 11 (20.0%)

Phase 22 (40.0%)

Phase 41 (20.0%)

Trials by Status

withdrawn240%

completed240%

unknown120%

Recent Activity

0 active trials

Showing 5 of 5

completedearly_phase_1

Biomarkers of Diet-microbiota Interactions in Irritable Bowel Syndrome

NCT04364750

withdrawnphase_4

Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease

NCT06169826

unknownphase_2

Clinical Trials (5)

Showing 5 of 5 trials

NCT04364750Early Phase 1

Biomarkers of Diet-microbiota Interactions in Irritable Bowel Syndrome

Completed

NCT06169826Phase 4

Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease

Withdrawn

NCT02924935Phase 2

Histidine Therapy: A Project to Treat HARS Deficiency

Unknown

NCT04764383Phase 2

Histaminergic Basis of Fatigue in Multiple Sclerosis

Withdrawn

NCT03266965Phase 1

Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach

Completed

All 5 trials loaded

Drug Details

Intervention Type: DIETARY SUPPLEMENT
Total Trials: 5